Breast Cancer Update

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:
Introduction: San Antonio Memories (0:00)
PI3K/AKT/PTEN Alterations and Therapies (7:18)
Capivasertib (20:22)
Gedatolisib (34:08)
Inavolisib (47:07)
New Agents and Ongoing Trials (52:34)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:43)
Potential Role of Combination Approaches with Oral SERDs (26:33)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
Emerging Utility of Adjuvant Oral SERDs (1:10:20)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)

CME information and select publications

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)
Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
Adjuvant CDK4/6 Inhibitor Therapy (17:14)
Practical Considerations with CDK4/6 Inhibitors (29:57)
Monitoring and Management of Cytopenias (42:02)
CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
Management of Gastrointestinal Adverse Events (1:03:47)
CDK4/6 Inhibitors in Unique Populations (1:10:41)
Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:
Introduction (0:00)
Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

CME information and select publications